comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 09:59:09 - browse：9

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Novo Nordisk to buy Cardior, building up pipeline of heart drugs

WSS

The surgeon had a dilemma only a Nazi medical text could resolve

Readout LOUD podcast, live from the STAT Breakthrough Summit East

FDA clears AI tool for detecting skin cancer

Biotech investment managers search for lucrative opportunities

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Dewpoint Therapeutics lays off staff after losing partnerships

Wikipedia

comprehensive

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Biotech investment managers search for lucrative opportunities

Alkermes shareholders re

Why doctors need education on FDA device approval process

Hepatitis C has a cure — but many Americans still lack access to it

Independent physicians launch a new lobbying group

Hepatitis C has a cure — but many Americans still lack access to it

Elizabeth Holmes banned from government health programs

State Dept. review finds Biden bears some blame for Afghanistan failures

Francis Collins on trust in science and how Covid communications failed

knowledge

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Pregnancy ages women, but effects reverse after delivery

My yearlong odyssey to get my son’s ADHD medication covered

The surgeon had a dilemma only a Nazi medical text could resolve

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

hotspot

explore

hotspot

focus